As a result, our findings should be regarded as hypothesis generating and require confirmation, although a recent meta-analysis of 22 trials involving 52 115 patients with a variety of conditions (including type 2 diabetes, chronic kidney disease, and heart failure) found that the use of an SGLT2 inhibitor was associated with a lower risk of VT reported as an adverse event (relative risk 0.73, 95% CI 0.53–0.99).43 Here, SLC5A2 is linked to chronic kidney disease.